Alamandine: Potential Protective Effects in SARS-CoV-2 Patients

Area of Science:

• Cardiovascular Biology
• Pulmonary Medicine
• Virology

Background:

• COVID-19, caused by SARS-CoV-2, lacks specific treatments and is linked to systemic inflammation and high mortality.
• COVID-19 pathogenesis involves the renin-angiotensin system (RAS), with SARS-CoV-2 entry via the ACE2 receptor.
• Disease severity is associated with imbalances in angiotensin II and Ang-(1-7)/alamandine, impacting pulmonary and cardiac tissues.

Purpose of the Study:

• To explore the role of the renin-angiotensin system (RAS) in COVID-19 pathogenesis.
• To investigate the protective mechanisms of alamandine and its pathway in mitigating SARS-CoV-2-induced injuries.
• To identify potential pharmacological targets for treating COVID-19 complications.

Main Methods:

• Review of existing literature on COVID-19, RAS, ACE2, and alamandine.
• Analysis of the molecular interactions between SARS-CoV-2 and the host's RAS.
• Examination of the anti-inflammatory and antifibrotic properties of alamandine via the MrgD receptor.

Main Results:

• COVID-19 severity correlates with RAS dysregulation and potential failure of protective pathways.
• High levels of ACE2 and Ang-(1-7) in some patients may indicate a compromised inflammatory response.
• Alamandine demonstrates antifibrotic effects through the Mas-related G protein-coupled receptor D (MrgD).

Conclusions:

• Understanding the RAS-alamandine-MrgD pathway is crucial for developing novel COVID-19 treatments.
• Targeting this pathway could inhibit SARS-CoV-2-induced pulmonary fibrosis and systemic inflammation.
• Alamandine represents a potential therapeutic agent for managing COVID-19-related organ damage.